Chapter 02

Our Strategy

Business andGlobal Expansion

Customer Voices

Innovative Solutions
to Improve Clinical Outcomes

We are proud to develop innovative solutions along the care pathway that improve clinical outcomes.
Here are two examples of novel solutions we recently introduced. Collaboration with healthcare providers wasessential for the development of these new solutions, and we share their clinical experiences below. In thefuture, we will continue to partner with leading healthcare providers to elevate the standard of care and shape abetter healthcare system.

ENDOCUFF VISION

iTindENDOCUFF VISION supports the early detection of colorectal cancer. The device
attaches to the distal end of a colonoscope and maximizes the viewable mucosa
during endoscopic therapy by manipulating colonic folds. A single row of flexible
arms evert and flatten folds to provide an enhanced view of the entire colon.

iTind is a non-surgical device supporting the minimally invasive treatment of benign
prostatic hyperplasia (BPH). The temporarily implanted nitinol device is placed in
the obstructed prostatic urethra in a folded configuration. The super-elastic nitinolstruts expand at the 12, 5, and 7 o’clock positions, reshaping the tissue to better
allow urine flow.	Clinician Benefits: ENDOCUFF VISION has been shown to increase adenoma
detection rates (ADR) by up to 16% over standard colonoscopies*1, improving
physicians’ abilities to detect and treat cancer in its early stages. Early detection
saves lives.	Patient Benefits: Supports easier colonoscopies with less pain and lessmucosal trauma.	Sales Regions: U.S., Europe, Asia Pacific	Future Growth Outlook: Double-digit growth (5-Year CAGR: FY2023-FY2028)

Customer Voices

Customer Voices

Dr. Douglas Rex

Dr. Bilal Chughtai

Indiana University Health (U.S.)

Weill Cornell Medicine (U.S.)

I utilize ENDOCUFF VISION in the great majority of routine colonoscopies I do. The
main advantage is that it improves detection. We know from the Kaiser study byDoug Corley that for each 1% increase in the ADR there’s a 3% reduction in thechance of colorectal cancer and a 5% reduction in the chance of fatal colorectal
cancer*2. There’s also a strong suggestion that there are some improvements inefficiency with ENDOCUFF VISION, and it’s really unusual to have a device thatimproves detection and at the same time makes you more efficient*3.”

Dr. Daniele Amparore

NYU Langone Medical Centre (U.S.)

Division of Urology, San Luigi Hospital (Italy)*1	Tsiamoulos ZP, Misra R, Rameshshanker R, Elliott TR, Beintaris I, et al., “Impact of a new distal attachment on colonoscopy performance in an academic screening center,” Gastrointest Endosc.
2018;87(1):280-287.
*2 Corley, D. A., Jensen, C. D., Marks, A. R., et al. “Adenoma detection rate and risk of colorectal cancer and death,” New England Journal of Medicine, 2014;370(14), 1298–1306.
*3	Quote is a complication of Dr. Rex’s comments in Episode 2: ENDOCUFF VISION and Its Benefits - https://medical.olympusamerica.com/products/endocuff-vision#forPhysicians and Episode 3:Adenoma Detection Rate - https://medical.olympusamerica.com/products/endocuff-vision*4 Webinar: The Art of Unfolding - https://youtu.be/dHmA9mEQZ40

Olympus Integrated Report 2023

The results of our randomized, controlled study demonstrate the safety andeffectiveness of the iTind, a temporarily implanted device, in reshaping the prostate
and allowing urine to flow, thus relieving lower urinary tract symptoms without theneed for patients to go home with a catheter. Most adverse events experienced bypatients during the trial were mild and resolved within two weeks, which is a majoradvantage over other therapies. Additionally, trial results showed that treatment with
the iTind does not compromise sexual function*5.”

Dr. Seth Gross

One of the things I really like and I have seen a tremendous benefit from early on isloop reduction. Loops are one of the biggest challenges when we do colonoscopies.
I have noticed that when I take a loop out with ENDOCUFF VISION, that loop tends
to stay out due to the way the fingers engage the colon. Furthermore, ENDOCUFFVISION allows me to better manipulate the colonic folds for a more carefulinspection. I can really see more of the surface area of the entire colon and identify
subtle polyps that would be otherwise hidden*4.”54	Clinician Benefits: iTind delivers rapid relief of BPH symptoms. It does notrequire cutting or heating prostate tissue, leaves behind no permanent implant,
and avoids complications associated with other treatments.	Patient Benefits: iTind preserves sexual function and continence and removes
the need for an uncomfortable catheter. It can be placed during a straightforward
procedure in an office or outpatient setting. Patients can recover at home.	Sales Regions: U.S. and Europe	Future Growth Outlook: Double-digit growth (5-Year CAGR: FY2023-FY2028)

We now have published study data showing iTind device treatment is a reliable
minimally invasive surgical option with minimal safety concerns for extended time
periods. This evidence of clinical durability is important to physicians considering
surgical options for BPH symptom treatment*6.”*5	Trial results published in Chughtai B, Elterman D, Shore N, et al. “The iTind temporarily implanted nitinol device for the treatment of lower urinary tract symptoms secondary to benign prostatic
hyperplasia: A multicenter, randomized, controlled trial” [published online ahead of print, 2020 Dec 26].Urology. 2020;S0090-4295(20)31520-X.
Quote published in https://www.goldjournal.net/article/S0090-4295(20)31520-X/fulltext published December 25, 2020 in Urology, a peer-reviewed medical journal known as the “Gold Journal”*6 	Amparore D, De Cillis S, Schulman C, et al. “Temporary implantable nitinol device for benign prostatic hyperplasia-related lower urinary tract symptoms: over 48-month results” [published online aheadof print, 2023 Jun 23]. Minerva Urol Nephrol. 2023;10.23736/S2724-6051.23.05322-3.
Note: Products or devices presented include future technology which may be pending regional regulatory approval and are not available for sale in all regions.

55